23. REMARKS:

LINDA MINAMOTO

HEALTH

ASSOCIATE REGIONAL ADMINISTRATOR

DIVISION OF MEDICAID & CHILDREN'S

advisory committee to be comprised of medical and pharmaceutical professionals regarding the pharmaceutical drugs that may be placed on a Preferred Drug List.

The State will appoint a Pharmacy and Therapeutics (P&T) Committee consisting of physicians and pharmacists or utilize the Drug Utilization Review (DUR) board in accordance with federal law.

(4) Supplemental Drug Rebate Agreements:

The State is in compliance with section 1927 of the Social Security Act. The state will cover drugs of federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions of coverage. Pharmaceutical manufacturers may audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.

The State will negotiate supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the state and a pharmaceutical manufacturer will be separate from the federal rebates.

A rebate agreement between the State and a drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on February 25, 2004 and entitled, State of Hawaii Supplemental Rebate Agreement, has been authorized by CMS.

Supplemental rebates received by the state in excess of those required under the national drug rebate program will be shared with the federal government on the same percentage basis as applied under the national drug rebate agreement.

All drugs covered by the program, irrespective of a supplemental rebate agreement, will comply with the provisions of the national drug rebate agreement.

TN No.	04-003							
Supersedes		Approval Date:	MAR	1	0	2004	Effective Date:	01/01/04
TN No.	03-004							